Latest Insider Transactions at Agios Pharmaceuticals, Inc. (AGIO)
This section provides a real-time view of insider transactions for Agios Pharmaceuticals, Inc. (AGIO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of AGIOS PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of AGIOS PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 26
2024
|
Cecilia Jones Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,542
-11.2%
|
$124,558
$49.03 P/Share
|
|
Sep 26
2024
|
Cecilia Jones Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,473
+24.77%
|
-
|
|
Aug 11
2024
|
Rahul D. Ballal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,302
+22.36%
|
-
|
|
Aug 11
2024
|
Cynthia Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,302
+22.36%
|
-
|
|
Aug 08
2024
|
Brian Goff Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,091
-12.34%
|
$465,822
$42.75 P/Share
|
|
Aug 08
2024
|
Brian Goff Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,691
+20.16%
|
-
|
|
Jul 01
2024
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,705
-7.81%
|
$159,315
$43.85 P/Share
|
|
Jul 01
2024
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,375
+15.0%
|
-
|
|
Jun 13
2024
|
Jacqualyn A Fouse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,388
+2.35%
|
-
|
|
Jun 13
2024
|
Kaye I Foster Cheek Director |
SELL
Bona fide gift
|
Direct |
3,564
-39.99%
|
-
|
|
Jun 13
2024
|
Kaye I Foster Cheek Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,388
+27.54%
|
-
|
|
Jun 13
2024
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,388
+2.61%
|
-
|
|
Jun 13
2024
|
Cynthia Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,388
+37.32%
|
-
|
|
Jun 13
2024
|
Rahul D. Ballal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,388
+37.32%
|
-
|
|
Jun 13
2024
|
Catherine E. Owen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,976
+50.0%
|
-
|
|
Jun 13
2024
|
David Scadden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,388
+17.95%
|
-
|
|
Jun 13
2024
|
Maykin Ho Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,388
+18.51%
|
-
|
|
Jun 13
2024
|
Jeffrey D Capello Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,976
+50.0%
|
-
|
|
Jun 05
2024
|
Brian Goff Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,115
-15.28%
|
$581,520
$48.84 P/Share
|
|
Jun 05
2024
|
Brian Goff Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,527
+24.35%
|
-
|
|
Jun 03
2024
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,362
-47.19%
|
$59,928
$44.39 P/Share
|
|
Apr 10
2024
|
Jacqualyn A Fouse Director |
SELL
Open market or private sale
|
Direct |
7,791
-5.37%
|
$210,357
$27.55 P/Share
|
|
Apr 08
2024
|
Jacqualyn A Fouse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,934
+9.89%
|
-
|
|
Mar 07
2024
|
Kaye I Foster Cheek Director |
SELL
Open market or private sale
|
Direct |
1,285
-18.87%
|
$39,835
$31.62 P/Share
|
|
Mar 06
2024
|
Kaye I Foster Cheek Director |
SELL
Open market or private sale
|
Direct |
4,415
-39.34%
|
$136,865
$31.99 P/Share
|
|
Mar 05
2024
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,127
-21.33%
|
$100,064
$32.3 P/Share
|
|
Mar 05
2024
|
Kaye I Foster Cheek Director |
SELL
Open market or private sale
|
Direct |
300
-2.6%
|
$9,600
$32.21 P/Share
|
|
Mar 05
2024
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,642
-3.38%
|
$84,544
$32.57 P/Share
|
|
Mar 05
2024
|
Cecilia Jones Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
672
-4.33%
|
$21,504
$32.57 P/Share
|
|
Mar 05
2024
|
Brian Goff Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,156
-7.17%
|
$132,992
$32.57 P/Share
|
|
Mar 05
2024
|
James William Burns Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,642
-3.56%
|
$84,544
$32.57 P/Share
|
|
Mar 01
2024
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,834
+9.12%
|
-
|
|
Mar 01
2024
|
Theodore James Washburn Jr. Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,127
+23.31%
|
-
|
|
Mar 01
2024
|
Cecilia Jones Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+11.42%
|
-
|
|
Mar 01
2024
|
Brian Goff Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+12.79%
|
-
|
|
Mar 01
2024
|
James William Burns Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,834
+9.54%
|
-
|
|
Feb 27
2024
|
David P Schenkein Director |
SELL
Open market or private sale
|
Direct |
69,329
-20.34%
|
$2,357,186
$34.24 P/Share
|
|
Feb 27
2024
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
69,329
+16.13%
|
$2,149,199
$31.64 P/Share
|
|
Feb 26
2024
|
David P Schenkein Director |
SELL
Open market or private sale
|
Direct |
20,411
-14.25%
|
$673,563
$33.19 P/Share
|
|
Feb 26
2024
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,411
+12.47%
|
$632,741
$31.64 P/Share
|
|
Feb 23
2024
|
David P Schenkein Director |
SELL
Open market or private sale
|
Direct |
47,731
-27.98%
|
$1,575,123
$33.05 P/Share
|
|
Feb 23
2024
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
47,731
+21.86%
|
$1,479,661
$31.64 P/Share
|
|
Feb 20
2024
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
504
-15.53%
|
$13,104
$26.63 P/Share
|
|
Feb 14
2024
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
273
-7.76%
|
$6,825
$25.14 P/Share
|
|
Feb 14
2024
|
James William Burns Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
545
-1.69%
|
$13,625
$25.14 P/Share
|
|
Feb 14
2024
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
642
-1.88%
|
$16,050
$25.14 P/Share
|
|
Feb 12
2024
|
Theodore James Washburn Jr. Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
777
+18.09%
|
-
|
|
Feb 12
2024
|
James William Burns Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,833
+5.38%
|
-
|
|
Feb 12
2024
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,162
+5.97%
|
-
|
|
Jan 24
2024
|
James William Burns Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,708
-5.32%
|
$35,868
$21.64 P/Share
|